497 related articles for article (PubMed ID: 8043879)
21. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
[TBL] [Abstract][Full Text] [Related]
22. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
Kumar D; Patil N; Husain S; Chaparro C; Bhat M; Kim SJ; Humar A
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28489256
[TBL] [Abstract][Full Text] [Related]
23. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
[TBL] [Abstract][Full Text] [Related]
24. The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
Preiksaitis J; Allen U; Bollard CM; Dharnidharka VR; Dulek DE; Green M; Martinez OM; Metes DM; Michaels MG; Smets F; Chinnock RE; Comoli P; Danziger-Isakov L; Dipchand AI; Esquivel CO; Ferry JA; Gross TG; Hayashi RJ; Höcker B; L'Huillier AG; Marks SD; Mazariegos GV; Squires J; Swerdlow SH; Trappe RU; Visner G; Webber SA; Wilkinson JD; Maecker-Kolhoff B
Pediatr Transplant; 2024 Feb; 28(1):e14471. PubMed ID: 37294621
[TBL] [Abstract][Full Text] [Related]
25. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
26. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients.
Hopwood PA; Brooks L; Parratt R; Hunt BJ; Bokhari M; Thomas JA; Yacoub M; Crawford DH
Transplantation; 2002 Jul; 74(2):194-202. PubMed ID: 12151731
[TBL] [Abstract][Full Text] [Related]
27. Antibody responses to two Epstein-Barr virus (EBV) nuclear antigens (EBNA-1 and EBNA-2) during EBV primary infection in children born to mothers infected with human immunodeficiency virus.
Pedneault L; Lapointe N; Alfieri C; Ghadirian P; Carpentier L; Samson J; Joncas J
Clin Infect Dis; 1996 Oct; 23(4):806-8. PubMed ID: 8909848
[TBL] [Abstract][Full Text] [Related]
28. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
29. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
30. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
31. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
32. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation.
Gridelli B; Spada M; Riva S; Colledan M; Segalin A; Lucianetti A; Sonzogni A; Furione M; Baldanti F; Torre G
Transpl Int; 2000; 13 Suppl 1():S399-401. PubMed ID: 11112041
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus latent gene EBNA-1 genetic diversity among transplant patients compared with patients with infectious mononucleosis.
Sullivan K; Isabel S; Khodai-Booran N; Paton TA; Abdulnoor M; Dipchand AI; Hébert D; Ng VL; Allen UD
Clin Transplant; 2019 Apr; 33(4):e13504. PubMed ID: 30790353
[TBL] [Abstract][Full Text] [Related]
34. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
35. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders.
Dharnidharka VR; Ruzinova MB; Chen CC; Parameswaran P; O'Gorman H; Goss CW; Gu H; Storch GA; Wylie K
Cancer Med; 2019 Mar; 8(3):1013-1023. PubMed ID: 30697958
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus infection in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Johnson SL; Klapper PE; Vallely PJ; Picton ML
Am J Transplant; 2014 Jul; 14(7):1619-29. PubMed ID: 24815922
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
[TBL] [Abstract][Full Text] [Related]
39. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
Wagner HJ; Wessel M; Jabs W; Smets F; Fischer L; Offner G; Bucsky P
Transplantation; 2001 Sep; 72(6):1012-9. PubMed ID: 11579293
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
